Published in Br J Cancer on October 01, 1995
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Clin Oncol (2014) 1.40
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer (2005) 1.06
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer (1999) 1.06
Prognostic impact of LDH levels in patients with relapsed/refractory seminoma. J Cancer Res Clin Oncol (2013) 0.84
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematol Oncol Clin North Am (2011) 0.82
Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. Br J Cancer (1996) 0.77
Efficacy of routine follow-up after first-line treatment for testicular cancer. World J Urol (2004) 0.75
Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med (1977) 4.91
Statistical aspects of prognostic factor studies in oncology. Br J Cancer (1994) 4.22
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med (1987) 3.52
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer (1991) 1.52
The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer (1992) 1.49
Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol (1989) 1.46
Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol (1991) 1.39
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer (1991) 1.36
Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol (1993) 1.29
The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol (1991) 1.21
Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med (1988) 1.03
Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis. Br J Cancer (1989) 1.01
Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol (1994) 1.00
Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol (1993) 0.98
High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer (1992) 0.96
Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol (1991) 0.95
Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br J Cancer (1993) 0.94
Salvage treatment in male patients with germ cell tumours. Br J Cancer (1993) 0.87
Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol (1995) 0.86
Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol (1995) 0.86
High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer (1993) 0.85
Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. Ann Oncol (1992) 0.84
Salvage therapy for germ cell tumors. Semin Oncol (1994) 0.84
The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours. Br J Urol (1994) 0.83
Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first-line chemotherapy for poor-risk non-seminomatous germ cell tumors. Acta Oncol (1993) 0.82
Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer (1994) 0.81
Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer (1993) 0.80
Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer. Clin Exp Metastasis (1994) 0.79
The value of ifosfamide in the polychemotherapy of metastasized testicular cancer pretreated with chemotherapy. Arzneimittelforschung (1982) 0.78
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 3.50
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer (1995) 2.12
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol (2009) 1.78
Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer (1993) 1.63
Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer. Lancet (1991) 1.60
Detection of somatic changes in human renal cell carcinomas with oligonucleotide probes specific for simple repeat motifs. Genes Chromosomes Cancer (1993) 1.40
Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol (1997) 1.33
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res (2001) 1.33
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 1.21
Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med (2001) 1.17
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie (2003) 1.17
Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol (1996) 1.14
Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant (2000) 1.14
Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer (2001) 1.13
Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood (1997) 1.07
Testicular cancer and Hodgkin disease in the same patient. Cancer (1993) 1.07
Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc (1993) 1.07
Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer (1999) 1.07
Resection of hypernephromas with vena caval or right atrial tumor extension using extracorporeal circulation and deep hypothermic circulatory arrest: a multidisciplinary approach. Eur J Cardiothorac Surg (1997) 1.06
Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol (1998) 1.04
Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem Pharmacol (1988) 1.03
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob Agents Chemother (1997) 1.01
Sludge decomposition and stabilization. Science (1981) 1.00
Identification of carcinoma cells in ascitic and pleural fluid. Comparison of four panepithelial antigens with carcinoembryonic antigen. Acta Cytol (1992) 0.95
Identification of membrane antigens in granulocytes and colonic carcinoma cells by a monoclonal antibody specific for biliary glycoprotein, a member of the carcinoembryonic antigen family. Cancer Lett (1991) 0.95
MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skeletal Radiol (1997) 0.94
Specific stages of cellular response to homeostatic control during diethylnitrosamine-induced liver carcinogenesis. Experientia (1970) 0.94
Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism. Br J Cancer (2006) 0.93
Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol (2000) 0.93
Elevated serum CA 125 levels in patients with benign ascitic or pleural effusions. Tumour Biol (1988) 0.93
Paraneoplastic chronic intestinal pseudoobstruction as a rare complication of bronchial carcinoid. Gut (1992) 0.93
Adoptive immunotherapy in canine chimeras. Transplantation (1997) 0.92
Epidermal growth factor receptors and epidermal growth factor-like activity in colorectal mucosa, adenomas and carcinomas. Klin Wochenschr (1989) 0.91
[Significance of immunoglobulins for the diagnosis and evaluation of the course of liver diseases]. Klin Wochenschr (1969) 0.90
Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9. Anticancer Res (1997) 0.90
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer (2004) 0.89
Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. J Clin Oncol (1990) 0.88
Tumour associated antigens in diagnosis of serous effusions. J Clin Pathol (1988) 0.87
Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol (1991) 0.87
Second malignancies after Hodgkin's disease: the Munich experience. Ann Hematol (1999) 0.87
[Infiltration patterns of plasmacytomas in magnetic resonance tomography]. Rofo (1996) 0.86
Characteristics of a peroxidase from the fresh-water crayfish Cambarus bartoni. Comp Biochem Physiol B (1973) 0.86
[Paramyloidosis, macroglossia and Raynaud's syndrome in Bence-Jones plasmacytoma]. Dtsch Med Wochenschr (1971) 0.86
Significance of CEA determinations in patients with cancer of the colon-rectum and the mammary gland in comparison to physiological states in connection with pregnancy. Bull Cancer (1977) 0.86
A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. Eur J Cancer (1993) 0.86
Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol (1995) 0.86
Inflammatory reactions induced by pretransplant conditioning--an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation? Leuk Lymphoma (1997) 0.85
Serial carcinoembryonic antigen (CEA) determinations in the management of metastatic breast cancer. Oncodev Biol Med (1980) 0.85
Quantitative correlation between the Dane particle-associated DNA polymerase and the hepatitis B e antigen. Infection (1979) 0.85
Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience. Cancer (1996) 0.85
Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res (1996) 0.85
GM-CSF for agranulocytosis. J Intern Med (1991) 0.84
Characteristics of arginase from the freshwater crayfish, Cambarus bartoni. Comp Biochem Physiol B (1971) 0.84
Hepatotoxicity following desflurane anesthesia. Hepatology (1999) 0.84
Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumour Biol (2002) 0.83
Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer (1994) 0.83
Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases. Lung (1994) 0.83
Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J Steroid Biochem Mol Biol (1993) 0.83
Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia (1999) 0.83
Non-invasive temperature mapping using MRI: comparison of two methods based on chemical shift and T1-relaxation. Magn Reson Imaging (1998) 0.83
Azathioprine lymphocytotoxicity. Potentially lethal damage by its imidazole derivatives. Arzneimittelforschung (1988) 0.83
Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first-line chemotherapy for poor-risk non-seminomatous germ cell tumors. Acta Oncol (1993) 0.82
Nitrogen metabolism in the terrestrial isopod, Oniscus asellus. Am Zool (1968) 0.82
Growth inhibition of human leukemic cell lines by the phenothiazine derivative fluphenazine. Anticancer Res (1993) 0.82
Repeated blast crisis (BC) of changing morphology, immunologic phenotype and cytogenetics in chronic myeloid leukemia (CML). Anticancer Res (1990) 0.82
DNA synthesis in leukemic cells under the action of cytotoxic agents in vitro and in vivo. Natl Cancer Inst Monogr (1971) 0.82
In vitro studies on the mechanism of hyperacute xenograft rejection. Transplant Proc (1971) 0.82
Drug-induced apoptosis in chronic lymphocytic leukemia. Leukemia (1999) 0.82
Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int J Cancer (2001) 0.82
Serum pharmacology of amphotericin B applied in lipid emulsions. Antimicrob Agents Chemother (1997) 0.82
Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res (2001) 0.82
Interleukin-3 enhances the endogenous leukotriene production. Blood (1993) 0.82
[Partial priapism. Case report and review of the literature of diagnostic and therapeutic measures]. Urologe A (1999) 0.82
[Fusion of an ectopic spleen with the left kidney. Preoperative diagnosis: adenocarcinoma of the kidney]. Urologe A (1985) 0.82